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Abstract
Objectives To evaluate at which sensitivity digital breast tomosynthesis (DBT) would become cost-effective compared to digital
mammography (DM) in a population breast cancer screening program, given a constant estimate of specificity.
Methods In a microsimulationmodel, the cost-effectiveness of biennial screening for women aged 50–75was simulated for three
scenarios: DBT for women with dense breasts and DM for women with fatty breasts (scenario 1), DBT for the whole population
(scenario 2) or maintaining DM screening (reference). For DM, sensitivity was varied depending on breast density from 65 to
87%, and for DBT from 65 to 100%. The specificity was set at 96.5% for both DM and DBT. Direct medical costs were
considered, including screening, biopsy and treatment costs. Scenarios were considered to be cost-effective if the incremental
cost-effectiveness ratio (ICER) was below €20,000 per life year gain (LYG).
Results For both scenarios, the ICER was more favourable at increasing DBT sensitivity. Compared with DM screening, 0.8–
10.2% more LYGs were found when DBT sensitivity was at least 75% for scenario 1, and 4.7–18.7% when DBT sensitivity was
at least 80% for scenario 2. At €96 per DBT, scenario 1 was cost-effective at a DBT sensitivity of at least 90%, and at least 95%
for scenario 2. At €80 per DBT, these values decreased to 80% and 90%, respectively.
Conclusion DBT is more likely to be a cost-effective alternative to mammography in women with dense breasts. Whether DBT
could be cost-effective in a general population highly depends on DBT costs.
Key Points
•DBTcould be a cost-effective screening modality for women with dense breasts when its sensitivity is at least 90% at a maximum
cost per screen of €96.
•DBT has the potential to be cost-effective for screening all women when sensitivity is at least 90% at a maximum cost per screen
of €80.
•Whether DBTcould be used as an alternative to mammography for screening all women is highly dependent on the cost of DBT
per screen.
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CDR Cancer detection rate
CHEERS Consolidated Health Economic
Evaluation Reporting Standards
DBT Digital breast tomosynthesis
DM Digital mammography
ICER Incremental cost-effectiveness ratio
LYG Life year gained
SE Standard error
SiMRiSc The simulation model on radiation
risk and breast cancer screening
Introduction
Breast cancer is one of the leading causes of death among
women, and the most common cancer in women—
approximately 1 in 8 women will develop breast cancer in
their lifetime [1]. National mammography screening programs
have been introduced in most European and developed coun-
tries for several decades. The key benefit of regular mammog-
raphy screening is that it detects breast cancer at an early stage
allowing more effective treatment and improved survival [2].
A recent study showed that the incidence of early-stage breast
cancer in patients who attend screening regularly is signifi-
cantly higher than that in patients who did not, suggesting a
stage shift to earlier detection with the implementation of reg-
ular screening [3]. However, there are also controversies re-
garding screening. Over-diagnosis and related over-treatment
are considered a main drawback of screening, with estimates
of over-diagnosis varying from 15 to 30% [4]. In addition,
false-positive results lead to unnecessary biopsies and nega-
tive psychological outcomes which can decrease the efficacy
and acceptability of screening programs [4]. A key issue is the
imperfect sensitivity of digital mammography (DM) which
reduces the effectiveness of screening [5].
It is well-documented that mammographic sensitivity de-
creases with increasing breast density [6]. Moreover, a higher
breast density is an additional risk factor for breast cancer, and
both false-positive and false-negative interpretations are more
likely with dense breasts [7]. Nowadays, digital breast
tomosynthesis (DBT) is gaining widespread attention because
it improves the detection of cancer particularly in dense breast
tissue. When using adjunct DBT in women with DM-negative
dense breasts, the ASTOUND-2 trial showed an incremental
cancer detection rate (CDR) of 2.83 per 1000 screens [8]. In
population-based screening, a recent meta-analysis showed
that DBT combined with DM yields a pooled incremental
CDR of 2.4 cancers per 1000 screens in biennial screening
practice with only a slight increase in recall rate compared to
DM alone [9]. With respect to the cost-effectiveness of DBT,
the evidence is limited. However, in a study focusing on US
population aged 50–74 years, biennial combined DM and
DBT screening for women with dense breasts was reported
to be cost-effective if the price of DBT plus DM was below
$226 [10]. Recently, synthesised 2Dmammograms fromDBT
were introduced showing similar sensitivity and specificity
with respect to DM [11]. This has made it feasible to use
DBT-only acquisition as a stand-alone screening modality in-
stead of combined DBT and DM [12].
In this evolving landscape for population breast screening,
we undertook a study aiming to evaluate at what sensitivity
DBT could be a cost-effective alternative to DM in a popula-
tion breast cancer screening program, while the specificity is
kept constant. Avalidated micro-simulation model (SiMRiSc)
was applied to simulate biennial population breast cancer
screening in The Netherlands for women 50–75 years of
age, whereby DBTwas applied to replace DM for all women
or, alternatively, for women with high breast density, against
DM screening as currently practiced. In doing so, we antici-
pate that the findings from this study could provide health-
economic evidence to the Dutch program and many organized
population screening programs practicing biennial DM
screening. However, we need to address other important is-
sues beyond health economics such as risk stratification and
estimates of incremental mortality impact, and recall rate
should also be taken into consideration before implementing
DBT in a population screening program [13].
Material and methods
This study was reported according to the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) state-
ment [14]. The simulation model on radiation risk and breast
cancer screening (SiMRiSc) was applied in the analysis
[15–17].
Description of the model and input variables
SiMRiSc is a micro-simulation Markov model that was pre-
viously published and externally validated in the general pop-
ulation and in women with BRCA gene mutations. In sum-
mary, women’s lifetimes were simulated considering their life
expectancy, chance of developing cancer, tumour growth,
probability of tumour self-detection and survival probability
from breast cancer. If a tumour was present at the screening
moment, the chance of detection was determined by the mam-
mographic sensitivity. The sensitivity is a function of breast
density which depends on the age of the woman. After breast
cancer diagnosis, either by screening or by self-detection, the
woman was removed from simulation and the breast cancer
age-specific death of the woman was calculated based on life
expectancy after diagnosis which depended on tumour size.
Also included were mammographic specificity for the intro-
duction of false positives, and the probability of tumour
Eur Radiol
induction due to the ionising radiation frommammography. In
the model, we assumed an 80% participation rate and only
invasive cancers were considered [18].
The estimates for the model variables were based on pub-
lished data for population statistics from The Netherlands and
the USA, results of systematic searches and published cost
estimates (Table 1) [15–27]. The population statistics used in
our study included cumulative lifetime risk of breast cancer,
mean onset age of breast cancer, breast density distribution
and participation rate, which are summarised in Table 1. In
this study, all sensitivities and specificities are given as mo-
dality sensitivity and modality specificity respectively [28].
Because DBT is a relatively new technique, there are no pub-
lished data on either breast density averaged sensitivity or
sensitivities based on breast density from a screening setting
with long follow-up. Therefore, we used a DBT sensitivity
that was constant across breast densities, and varied the sen-
sitivity values from 65 to 100% in steps of 5%, with a lower
boundary set at the minimum estimate for DM sensitivity [25].
The DBT specificity was fixed at 96.5%, which was the same
as the specificity of DM [24]. The cost of mammography in
the Dutch national screening program was determined as the
cost of the whole program divided by the number of partici-
pants [18]. The base price for DBTwas estimated at 1.5 times
the DM costs, i.e. €96 per screen, allowing for a conventional
cost-effectiveness estimate, given the higher equipment costs,
added digital storage capacity, more expensive reading sta-
tions and the double-reading time for DBT [29].
Additionally, a lower estimated cost for DBT was also simu-
lated, which was 1.25 times the DM cost, i.e. €80 per screen.
Table 1 Input variables and their estimates for the SiMRiSc model
Variable Mean estimate (SD) Reference
Population Cumulative lifetime breast cancer risk at the age of 70 22.6% (0.74) [19]
Mean onset age of breast cancer 72.9 (1.1)
SD in onset age of breast cancer 21.1 (0.93)
Breast density distribution Age group BI-RADS density [20–22]
1 2 3 4
< 40 5% 30% 48% 17%
40–50 6% 34% 47% 13%
50–60 8% 50% 37% 5%
60–70 15% 53% 29% 3%
> 70 18% 54% 26% 2%
Participation rate 80% [18]
Tumour induction model Excess relative risk of tumour induction
due to radiation per Gy
0.51 (0.16) [17]
Tumour growth model Tumour doubling time per age group < 50 80 (28) days [23]
50–70 157 (25) days
> 70 188 (52) days
Digital mammography Sensitivity BI-RADS density [15]
1 2 3 4
87% 84% 73% 65%
Specificity 96.5% [24]
Cost/screen €64 [25]
Mean glandular dose 3.0 (1.0) mGy [17]
Detection threshold 5 mm [26]
Digital breast tomosynthesis Sensitivity* 65–100% [25]
Specificity 96.5% [24]
Costs/screen €96 /€80
Mean glandular dose 4.0 (1.3) mGy [26]
Detection threshold 5 mm [17]
Costs in case of positive finding Biopsy €176 [27]
Treatment (tumour diameter) < 2 cm €6438 [16]
2–5 cm €7128
> 5 cm €7701
*For sensitivity of DBT, the lower boundary was set at the minimum estimate for the DM sensitivity
SD = standard deviation
Eur Radiol
A detailed description of other input variables can be found in
our previous studies [15–17].
Screening scenarios
Three screening scenarios were evaluated. In the first scenario,
DBT was used for biennial breast cancer screening only for
women with high-density breasts (BI-RADS 4th edition den-
sity scores 3 and 4), whereas DM was used for women with
non-dense breasts (scenario 1). The breast density distribution
was described as a percentage, according to age group, as
defined in Table 1. In the second scenario, DBT was used
for biennial breast cancer screening for all women aged 50–
75 (scenario 2). The current breast cancer screening program
in The Netherlands, biennial mammography screening with
DM for women aged 50–75 years, was simulated as a refer-
ence scenario. To make appropriate comparisons among sce-
narios, we used the same input variables of population statis-
tics, tumour induction model and tumour growth model; how-
ever, the modality-related variables such as cost, dose and
sensitivity were varied according to the specific modality
used.
Outcome of the simulation model
One hundred thousand women were simulated for all three
scenarios in order to minimise the statistical error and keep
the computation time within limits (approximately 0.15 min
for each simulation on a PC workstation). Each simulation
was repeated 10 times in order to calculate the error of the
point estimates. The sensitivity of DBTwas varied between 65
and 100% in steps of 5%. The results from the simulations
were reported in terms of the number of screen-detected tu-
mours, the number of interval cancers and the number of life
years gained (LYG) for both DBTscreening scenarios as com-
pared to the reference. All results and the standard errors (SEs)
were calculated based on the outcomes of the simulation
repetitions.
Cost-effectiveness analysis
Only direct medical costs were considered in this study, in-
cluding the screening costs for different modalities, the treat-
ment costs based on the tumour size and related biopsy costs
due to positive screening results. Incremental cost-
effectiveness ratios (ICER) for both DBT screening scenarios
were estimated as the ratio of the additional costs to the addi-
tional LYG compared to the reference, and ICER was also
estimated between the two DBT scenarios. The ICER thresh-
old was set to €20,000 per LYG [30]. Discounting is the pro-
cess of converting future costs to their present value; to reflect
the fact that, in general, society prefers to receive benefits
sooner rather than later, and pays costs later rather than sooner
[31]. A discount rate of 3% for both costs and effects was
applied allowing for international comparisons [32].
Additionally, a discount rate of 4% for costs and 1.5% for
health effects (LYG) was applied according to the Dutch
guidelines [33]. In the main text, all ICERs are reported as
international discounted ICERs; the undiscounted and Dutch
discounted ICERs are provided in the supplementary file.
Results
The reference scenario of DM screening resulted in a cumu-
lative count of 536 screen-detected cancers, 272 interval can-
cers and 1353 LYG when 10,000 women were screened bien-
nially from age 50 to 74 years. The results based on modelled
sensitivity of DBT showed that the effectiveness of both DBT
scenarios increased at increased DBT sensitivity (Table 2) as
more screen-detected tumours, fewer interval tumours and
more LYG were observed. When the sensitivity of DBT was
lower than 72%, both DBT scenarios were less effective than
the reference scenario. Generally, compared to the reference
(DM), the ICER for both DBT scenarios became more
favourable with increasing DBT sensitivity.
Scenario 1: DBT screening only for women with dense
breasts
DBT screening only for women with dense breasts was the
most effective scenario when the sensitivity of DBT was at
least 72% (Table 2). Compared with the reference, when a 3%
discounting rate was applied, at a cost of €96, scenario 1 was
cost-effective at a sensitivity of approximately 86% (Table 3
and Fig. 1a), whereas at a cost of €80, scenario 1 became cost-
effective when DBT sensitivity was at least 80%. (Table 3 and
Fig. 1b).
Scenario 2: DBT for whole population
At a DBT sensitivity of 80%, the effectiveness of screening
with DBT was comparable to screening with DM regarding
the number of screen-detected cancers, interval cancers and
LYGs (Table 2). When the sensitivity of DBT was > 85%,
scenario 2 was the most effective resulting in at least 26 more
screen-detected cancers, 19 fewer interval cancers and 64
more undiscounted LYG per 10,000 women than biennial
DM screening (Table 2). However, at a cost of €96, scenario
2 would not be cost-effective unless the sensitivity of DBT
was larger than 95% when a 3% discounting rate was applied
(Fig. 1a). However, if the cost of DBT decreased to €80,
scenario 2 could be cost-effective when DBT sensitivity was
around 90% (Fig. 1b).
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Scenario 2 compared with scenario 1
When DBT sensitivity was lower than 85%, scenario 2 was
always dominated by scenario 1. At a cost of €96, scenario 2
could never be cost-effective even the sensitivity of DBTwas
100% when discounted by international rate (Fig. 1a), where-
as scenario 2 could be cost-effective than scenario 1 w hen the
sensitivity of DBTwas around 95% at a cost of €80(Fig. 1b).
Discussion
Our simulation modelling showed that for women aged 50–
75 years, biennial screening with DBT for women with dense
breasts is cost-effective when the sensitivity is around 90%
(depending on the international discount rate), whereas DBT
is unlikely to be a cost-effective alternative to DM if used to
screen the general population when the cost of DBT is €96.
Table 2 Screening outcomes of using biennial DBT in a population screening program
Sensitivity of DBT 65% 70% 75% 80% 85% 90% 95% 100%
DBT for dense breasts compared to DM (scenario 1–reference)
N screen-detected − 12 (0) − 3 (0) + 6 (0) + 15 (0) + 24 (1) + 31 (1) + 40 (1) + 47 (1)
N interval + 12 (0) + 4 (0) − 4 (0) − 12 (0) − 19 (0) − 25 (0) − 32 (1) − 39 (1)
LYG − 39 (2) − 14 (2) + 12 (2) + 40(4) + 63 (4) + 88 (5) + 115(5) + 138(5)
Discounteda LYG − 14 (1) − 5 (1) + 5(1) + 19 (2) + 30 (2) + 42 (2) + 54 (2) + 65 (2)
Discountedb LYG − 23 (1) − 8 (1) + 8 (2) + 27 (3) + 43 (3) + 60 (3) + 78 (3) + 94 (3)
DBT for all women compared to DM (scenario 2–reference)
N screen-detected − 74 (1) − 47 (1) − 22 (1) + 2(1) + 26(1) + 48 (0) + 71 (0) + 91 (1)
N interval + 66 (1) + 43 (1) + 21 (0) + 1(1) − 19 (0) − 38 (1) − 57 (0) − 74 (1)
LYG − 219 (3) − 146 (4) − 76 (3) − 5 (4) + 64 (4) + 129 (3) + 195 (4) + 254 (5)
Discounteda LYG − 76 (1) − 51 (1) − 25 (1) + 3 (2) + 31 (2) + 62 (3) + 92 (2) + 120 (3)
Discountedb LYG − 126(2) − 84(2) − 43(2) + 1 (3) + 44 (3) + 88 (4) + 133 (3) + 172 (4)
DBT for all women compared to DBT for dense breasts (scenario 2–scenario 1)
N screen-detected − 62(1) − 44(1) − 28(1) − 13(0) + 3(0) + 17(1) + 31(1) + 44(1)
N interval + 54(1) + 39(0) + 25(1) + 12(0) 0(0) − 12(0) − 24(1) − 35(1)
LYG − 180(3) − 132(4) − 88(3) − 45(2) + 1(1) + 41(2) + 80(3) + 117(3)
Discounteda LYG − 62(1) −46(1) − 30(1) − 16(1) + 1(0) + 19(1) + 38(1) + 54(1)
Discountedb LYG − 104(2) − 76(2) − 51(2) − 26(1) + 1(1) + 28(1) + 54(2) + 79(2)
Data shown as differences in number of DBT screen-detected tumours (N screen-detected) and number of interval tumours (N interval) for scenarios 1
and 2 with respect to the reference scenario of biennial DM screening for women 50–75 years of age, and for scenario 2 with respect to scenario 1. All
data expressed as mean (SEs) per 10,000 women screened. Discountinga : 3% for both cost and LYG. Discountingb : 4% for cost and 1.5% for LYG
N = number; LYG = life years gained; DM = digital mammography; DBT = digital breast tomosynthesis.
Values in italics indicate the scenario ourperforms the comparison in the screening outcome
Table 3 The cost-effectiveness of























65 – – – – – –
70 – – – – – –
75 180.3 (37.4) – – 91.1 (18.9) – –
80 41.0 (3.8) – – 20.8 (1.9) – –
85 24.4 (1.6) 63.7 (4.5) – 12.4 (0.8) 32.2 (2.3) –
90 17.3 (0.8) 31.3 (1.3) 61.9 (2.6) 8.8 (0.4) 15.9 (0.7) 31.3 (1.3)
95 13.2 (0.5) 20.8 (0.5) 31.9 (0.9) 6.7 (0.2) 10.6 (0.3) 16.2 (0.5)
100 11.0 (0.3) 16.0 (0.4) 22.1 (0.6) 5.6 (0.2) 8.2 (0.2) 11.2 (0.3)
Data are reported as incremental cost-effectiveness ratios (ICERs) with associated standard errors. ICERs are
expressed as 1000 euros per LYG. A discount rate of 3% was applied to costs and life years gained. Data which
not shown in the table indicates that the specific scenario was dominated by the comparator
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However, if the price of DBT decreased to €80, the sensitiv-
ities to be cost-effective would decrease to 80% and 90% for
scenarios 1 and 2, respectively. Our findings may be of imme-
diate relevance to policymakers considering population breast
cancer screening programs with DBT, or those planning
density-tailored screening scenarios.
Instead of using a point estimate for DBT sensitivity, we
used a sensitivity range to estimate the lowest sensitivity at
which DBT would be cost-effective in a population breast
cancer screening program, given the range of published
DBT sensitivities. In population-based screening programs,
the performance of DBT showed a similar or slightly higher
sensitivity compared to DM, and the DBT sensitivity was
varied between 81.1 and 91.6% [12, 34–36]. A recent meta-
analysis restricted to women with dense breasts showed that
the sensitivity of DBTor DBT plus DMwas higher (84–90%)
than DM alone (69–86%) [37]. Given the range of sensitivity
values, the required threshold sensitivity in our findings sug-
gests that only when the cost of DBT was around €80, DBT
could be a cost-effective alternative to DM when applied for
screening the whole population at a sensitivity of 90%.
However, no matter which value of these two DBT costs is
used, DBTscreening only for womenwith dense breasts could
be cost-effective, since the threshold for dense breasts is with-
in the reported DBTsensitivity range. Another important issue
is that previous studies have shown that DBT detects more
tumours than DM [36, 38]. Therefore, the sensitivity of DM is
likely to be overestimated when cancers that are only detected
by DBT are not taken into account (unless there has been
adequate follow-up). However, in a recent study using DM
and DBT in over 24,000 women where DBT-only cancers
were also counted, the modality sensitivity of DM was ap-
proximately 80% which is comparable to the overall modality
sensitivity of 79% used in our study [36]. Nevertheless, as it is
likely that there might still be some overestimation of DM
sensitivity, this might lead to a slight underestimation of
DBT cost-effectiveness. We expect, however, that this would
not influence the main outcomes of our study.
DBT for population screening is becoming more wide-
spread in some settings, based on cancer detection and recall
metrics; however, there is limited evidence on whether DBT
could be a cost-effective alternative to DM in a population
screening program, and little knowledge exists on its long-
term outcomes. Only two studies have so far compared the
cost-effectiveness of DBT plus DM to DM for breast cancer
screening, both done in the USA [10, 39]. Lee et al simulated
biennial DBT plus DM among women aged 50–74 years with
dense breasts using a discrete-event model, and the estimated
sensitivity of DBT plus DM was 80%, which was lower than
our estimated threshold [10]. The ICER was $53,893 which
was considered to be cost-effective using a US threshold of
$100,000 per QALY [40]. In our study, using a DBT sensitiv-
ity of 80%, at the cost of €96, the ICER for women with dense
breasts was €41,021per LYG, generally similar results to Lee
et al [10]. Kalra et al simulated annual DBT plus DM among
women aged 40 years and older using a Markov cohort
decision-analytic model [39]. The ICER was $20,230 per
QALY, which was much lower than the ICER of screening
the whole population as shown in our study.
The cost-effectiveness of DBT screening is highly depen-
dent on the cost of DBT per examination. There are many
factors that can influence DBTcosts. Reading time is the main
indirect cost related to DBT screening. Reading DBT images
roughly doubles the interpretation time for mammograms
[29]. Secondly, the price of new digital mammographic units
with DBT capability entails an upfront investment [41]. A
dedicated workstation is also needed to interpret DBT images,
also requiring additional funding [41]. Information technolo-
gy and image archiving infrastructure is substantially higher
for DBT, for example DBT storage space can be 100 to 200
times that of DM [41]. In previous studies from the USA, the
costs of adjunct DBT are found to be around 30–40% higher
compared to DM alone [10, 39], while the To-Be trial in
Norway reported an incremental screening cost of €8.5 per
screen [42]. However, the cost estimated in the To-Be trial
might be underestimated. Firstly, the screening machines ran
Fig. 1 The discounted
incremental cost-effectiveness ra-
tio (ICER) as a function of the
sensitivity of digital breast
tomosynthesis (DBT) at a DBT
cost of €96 (a), or at a DBTcost of
€80 (b). Discount rate of 3% was
applied to costs and life years
gained. Scenario 1: DBT for
women with dense breast; sce-
nario 2: DBT for whole popula-
tion; reference: DM for whole
population. Abbreviations:
ICER = incremental cost-
effectiveness ratio
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at a 100% capacity throughout the study period, which might
not always be the case in practice. Secondly, the cost per
screen depends on the number of women screened, and the
trial was conducted in a city with a large population density,
the cost might be higher when generalised to a population
program. Therefore, in our study, we used two estimated
values, a conventional estimate for the price of DBT at 50%
higher than DM, and a 25% higher estimate based on expert
opinion.
Regarding specificity, there is no consensus on whether
DBT specificity is improved compared to DM. Some studies
showed that specificity can be improved with adjunct DBT
compared to DM alone [43, 44]. However, a meta-analysis
addressed that the recall rate of adjunct DBT increased slightly
in European countries, where the recall rate of DM was rela-
tively low compared to other regions such as the USA [9]. In
addition, the Malmö screening trial, a prospective study con-
ducted in Sweden, reported an increase in false positive recall
rate for one-viewDBTcompared with two-viewDM (1.7% vs
0.9%, respectively) [12]. In a recent meta-analysis restricted to
women with dense breasts, the improvement in specificity
from DBTwas found to be inconsistent in a screening setting
[37]. Because of these inconsistent results, the specificity of
DBT in our analysis was fixed at a conventional estimate
value of 96.5%, which was the same as the specificity of DM.
Our study used a validated model for which a sensitivity
analysis has been done in a previous study indicating that the
outcomes of the model were most sensitive to changes in the
lifetime risk of breast cancer [17]. In our model, the sensitivity
of DM depends on breast density and age, so increasing age
generally leads to a decrease in breast density and to a corre-
sponding increase in sensitivity of DM. This is an important
component to consider as approximately 36% of Dutch wom-
en have dense breasts [45]. In addition, the model includes an
increased risk of cancer induction due to radiation dose, which
was not considered in previous studies that investigated the
cost-effectiveness of DBT as a screening modality [10, 39].
Although we used a relatively higher dose for DBT compared
to DM (4 mGy vs 3 mGy, respectively), only 0.4% more
tumours were introduced by the increased dose. Therefore,
we estimate that the influence of the increased dose from
DBT has a negligible influence on the outcomes of our model.
As to limitations of the study, we point out that ductal
carcinoma in situ is not included in this model. DCIS
accounts for nearly 20% of the DM screen-detected tu-
mours in the Dutch population and similar proportions
are detected in other population screening programs [18,
46]. However, previous studies have shown that DBT plus
DM can increase invasive CDR without preferentially in-
creasing the proportion of DCIS compared to DM alone
[47]. So, we expect that addition of DCIS into the model
would not substantially change the major outcomes of the
analysis. Another potential limitation is that we used
values for DM sensitivity generated using meta-analysis
[15]; this included some studies that were based on
single-reading screening setting, suggesting that DM sen-
sitivities might be lower compared to double-reading
screening setting. The cost-effectiveness of DBT would
be overestimated especially for scenario 2, where DBT
was used for the whole population. Thirdly, it has been
shown that specificity increases with a decrease in breast
density [22]. There is, however, no reliable data on the
dependence of specificity on breast density for DBT.
Therefore, as a first-order estimation, we used a constant
specificity which was independent of breast density in our
model. Nevertheless, if a similar decrease in specificity
for both DBT and DM was applied in dense breasts, the
ICER in our study would not be influenced as the number
of false positives would be similar for both DBT and DM,
making the incremental cost nearly unchanged. In addi-
tion, when implementing scenario 1 in practice, it is likely
that every woman would get a DBT examination in the
first screening round in order to assess breast density from
the synthetic mammogram. This results in a 1.1% increase
in total costs. Therefore, in order for scenario 1 to be cost-
effective, the sensitivity of DBT increases to 92% at a
cost of €96 and approximately 85% at a cost of €80 per
screen. Finally, we modelled the modality sensitivity of
DBT, where we evaluated the effectiveness of a screening
program. Because DBT is a relatively new technique,
there are no data available on the sensitivity of a screen-
ing program including DBT, as long follow-up is needed
to obtain reliable estimates of program sensitivity [28].
Conclusion
Several European countries, and Australia, have recently
evaluated DBT in trials performed in population-based
screening programs [12, 35, 36, 48]. However, DBT is a
relatively new technology, and whether DBT could be an
alternative cost-effective replacement for DM in a popu-
lation screening program is a matter of ongoing investi-
gations. Based on our analysis, DBT is more likely to be a
cost-effective alternative to DM in women with dense
breasts. The threshold sensitivity for DBT to be cost-
effective is 90% and 80% at €96 and €80, respectively.
Whether DBT could be cost-effective in a general popu-
lation highly depends on the DBT cost. We envisage that
a differential screening scenario in a population screening
program (such as the proposed DBT only for dense
breasts) requires innovative studies and trials to determine
how this could be evaluated in pragmatic implementation
studies. Such an approach would also require consider-
ation of ethical issues and stakeholder consultation.
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